Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PHOTONIS Resource Report Resource Website 10+ mentions |
PHOTONIS (RRID:SCR_003853) | PHOTONIS | commercial organization | Commercial organization that manufactures Vacuum Electron Devices and Associated RF Circuits for Communications, Science, Radar, Industry & Directed Energy Applications. Other products include photo-detectors for scientific and medical applications and specialized material processing and plating services. | optical sensor, detector, night-vision, imaging, photo, power tube, rf cavity, photo-detector, photo detection, light sensor, surveillance, surface treatment, plating, optic, goggle, rifle sight, monocle | is related to: READNA | nlx_158234 | SCR_003853 | PHOTONIS USA Pennsylvania, PHOTONIS USA PENNSYLVANIA INC. | 2026-08-15 11:22:42 | 32 | ||||||||
|
Blueprint Epigenome Resource Report Resource Website 100+ mentions |
Blueprint Epigenome (RRID:SCR_003844) | BLUEPRINT | portal, data or information resource, protocol, consortium, organization portal | Consortium to further the understanding of how genes are activated or repressed in both healthy and diseased human cells with a focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukemic counterparts. They will generate at least 100 reference epigenomes and study them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. Reference epigenomes will be generated by state-of-the-art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by International Human Epigenome Consortium (IHEC). Access to the data is provided as well as the protocols used to collect the different blood cell types, to perform the different types of epigenomic analyses, etc.). This resource-generating activity will be complemented by hypothesis-driven research into blood-based diseases, including common leukemias and autoimmune disease (Type 1 Diabetes), by discovery and validation of epigenetic markers for diagnostic use and by epigenetic target identification. Since epigenetic changes are reversible, they can be targets for the development of novel and more individualized medical treatments. The involvement of companies will energize epigenomic research in the private sector by the development of smart technologies for better diagnostic tests and by identifying new targets for compounds. Thus the results of the project may lead to targeted diagnostics, new treatments and preventive measures for specific diseases in individual patients, an approach known as "personalized medicine". The Blueprint Data Access Committee will consider applications for access to data sets stored in the European Genome-phenome Archive (EGA) when authorized to do so by the Blueprint consortium and the holders of the original consent documents. Access is conditional upon availability of samples and/or data and signed agreement by the researcher(s) and the responsible employing Institution to abide by policies related to publication, data disposal, ethical approval and confidentiality. At EBI, the ftp site with the data can be found. You can either opt to link to the track hubs yourself or you can add the track hub to a genome browser - UCSC or ENSEMBL. Also Meta Data files and README are available. The data can also be accessed via the BIOMART system. | epigenome, hematopoiesis, gene, data set, biomaterial supply resource, antibody, blood cell, blood, cord blood precursor cell, cell, cord blood, bone marrow, rna-seq, dname-seq, dnasei-seq, chip-seq, monocyte, granulocyte neutrophil, eosinophil, macrophage, m0, m1, m2, naive cd4+, naive cd8+, pathway |
uses: European Genome phenome Archive uses: European Bioinformatics Institute uses: BioMart Project uses: UCSC Genome Browser uses: Ensembl is used by: Deep Blue Epigenomic Data Server is listed by: Consortia-pedia is listed by: One Mind Biospecimen Bank Listing has parent organization: Radboud University; Nijmegen; The Netherlands |
Leukemia, Blood disease, Autoimmune disease, Type 1 diabetes, Diabetes | European Union FP7 282510 | Authorization required, Application required, Data Access Agreement, Acknowledgement required | nlx_158155 | SCR_003844 | BLUEPRINT - A BLUEPRINT of Haematopoietic Epigenomes | 2026-08-15 11:22:36 | 123 | |||||
|
CHEM21 Resource Report Resource Website 1+ mentions |
CHEM21 (RRID:SCR_003848) | CHEM21 | organization portal, data or information resource, consortium, portal | A European public-private consortium examining ways to make chemical research and the pharmaceutical industry more sustainable and environmentally friendly with the aim of developing sustainable biological and chemical alternatives to finite materials, such as precious metals, which are currently used as catalysts in the manufacture of medicines. The project has looked at the industry and identified needs and barriers, and is now working to develop methods to navigate around them to reduce costs for companies and thus reduce prices for patients. Chem21 also involves an educational training component that will help instill the project's results in the next wave of scientists. The project has four focus areas that are driving it toward the desired impact on the 21st century pharmaceuticals industry: * New, more efficient catalyst classes made available for greening processes and the generation of novel molecules * Alternative methodologies clearly described to allow broader use * New modified microorganisms for preparing pharma building blocks disclosed * Training materials developed for driving longer-term innovation | drug, environment, drug development, chemical catalyst, biosynthetic pathway, chemistry, pharmaceutical industry, training resource, green chemistry, drug manufacturing |
is listed by: Consortia-pedia has parent organization: University of Manchester; Manchester; United Kingdom |
Innovative Medicines Initiative ; EFPIA |
nlx_158163 | SCR_003848 | Chemical Manufacturing Methods for the 21st Century Pharmaceutical Industries, CHEM21.eu, Chemical Manufacturing Methods for the 21st Century Pharmaceutical Industries (Chem21) | 2026-08-15 11:22:39 | 4 | |||||||
|
European Lung Foundation Resource Report Resource Website 1+ mentions |
European Lung Foundation (RRID:SCR_003842) | ELF | topical portal, funding resource, portal, data or information resource, disease-related portal | Foundation with aim of bringing together patients, the public and respiratory professionals to positively influence lung health and respiratory medicine. ELF aims to communicate respiratory science to those outside of the respiratory field, to ensure that people with lung diseases and the general public have a chance to influence respiratory research and guidelines at a European level. | lung, respiratory |
is related to: EARIP is parent organization of: AirPROM |
Lung disease | nlx_158176 | SCR_003842 | Euro Lung Foundation | 2026-08-15 11:22:42 | 3 | |||||||
|
Elephant Resource Report Resource Website 10+ mentions |
Elephant (RRID:SCR_003833) | Elephant, ElePhAnT | software toolkit, data processing software, software application, data analysis software, software resource | The Electrophysiology Analysis Toolkit (Elephant) is a Python library that provides a modular framework for the analysis of experimental and simulated neuronal activity data, such as spike trains, local field potentials, and intracellular data. Elephant builds on the Neo data model to facilitate usability, to enable interoperability, and to support data from dozens of file formats and network simulation tools. Its analysis functions are continuously validated against reference implementations and reports in the literature. Visualizations of analysis results are made available via the Viziphant companion library. Elephant aims to act as a platform for sharing analysis methods across the field. | electrophysiology, analysis, spike train, local field potential, python |
uses: Neo uses: NumPy uses: SciPy is used by: NetworkUnit has parent organization: NeuralEnsemble |
PMID:31449837 | Free, Available for download, Freely available | nlx_158148 | https://github.com/NeuralEnsemble/elephant | SCR_003833 | Elephant - Electrophysiology Analysis Toolkit, Electrophysiology Analysis Toolkit | 2026-08-15 11:22:39 | 30 | |||||
|
National Kidney Foundation Resource Report Resource Website 10+ mentions |
National Kidney Foundation (RRID:SCR_003990) | NKF | institution | Organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease. Initiatives include public and professional education, kidney health screenings, research, and patient services. They publish a number of scientific journals including the American Journal of Kidney Diseases, Advances in Chronic Kidney Disease and the Journal of Renal Nutrition. The NKF also publishes the Kidney Dialysis Outcomes Quality Initiative K/DOQI, a comprehensive set of clinical practice guidelines. (Adapted from Wikipedia) | kidney, organ, donation, transplantation, nephrology, clinical, training resource, narrative resource, standard specification | is related to: Kidney Health Initiative | Kidney disease | Crossref funder ID: 100003066, Wikidata: Q6973913, nlx_158404, grid.419687.5, ISNI: 0000 0001 1958 7479 | https://ror.org/01n45xa04 | SCR_003990 | National Kidney Foundation | 2026-08-15 11:22:43 | 18 | ||||||
|
Enzo Life Sciences Resource Report Resource Website 10+ mentions |
Enzo Life Sciences (RRID:SCR_003900) | commercial organization | An Antibody supplier | nlx_152356, grid.482398.c, ISNI: 0000 0004 0375 3702 | https://ror.org/00cezwy16 | SCR_003900 | Alexis, Assay Designs, BIOMOL, Enzo Life Sciences inc., Stressgen Bioreagents | 2026-08-15 11:22:44 | 35 | ||||||||||
|
MediBeacon Resource Report Resource Website 10+ mentions |
MediBeacon (RRID:SCR_003987) | MediBeacon | commercial organization | A commercial optical diagnostic company focused on providing clinicians with critical information to improve patient care. The Optical Renal Function Monitor (ORFM) is their first product platform and is focused on real-time, easy to use, and cost-effective monitoring of kidney function. Their non-invasive monitoring technology works in a similar fashion to pulse oximetry by using a light sensor placed on the skin. After the sensor has been placed, a proprietary biocompatible tracer is administered. The system can then monitor the patient''s real-time point-of-care kidney function. This information will allow for earlier detection of renal issues enabling clinicians to provide earlier, and hence more effective interventions. MediBeacon has created a research grade technique that is clinically applicable for real-time point-of-care Glomerular Filtration Rate measurement (mGFR). MediBeacon has invented a fluorescent tracer agent (MB-102) that is removed from the blood exclusively by the GFR mechanism of the kidneys. Together with their non-invasive detection device, this will deliver a real-time point-of-care measurement of GFR. | kidney function, kidney, patient care, clinical, nephrology, glomerular filtration rate, medical device |
is related to: Kidney Health Initiative is parent organization of: MediBeacon Studio Software |
Kidney disease | nlx_158398 | SCR_003987 | MediBeacon LLC | 2026-08-15 11:22:40 | 33 | |||||||
|
Mallinckrodt Pharmaceuticals Resource Report Resource Website 1+ mentions |
Mallinckrodt Pharmaceuticals (RRID:SCR_003986) | Mallinckrodt | commercial organization | An independent global pharmaceutical company that produces specialty pharmaceutical products including generic drugs and imaging agents. They manufacture and distribute products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals. They are the largest U.S. supplier, by prescription, of opioid pain medications and the largest U.S. supplier of the medical isotope technetium-99m. The company is among the top 10 generic pharmaceuticals manufacturers in the United States. The company is also the largest producer of bulk acetaminophen. Mallinckrodt also produces cocaine derived from the Coca-Cola coca leaves, extracted by the Stepan Company. (Adapted from Wikipedia, 10/2014) | pharmaceutical, drug, analgesic, neurology, rheumatology, nephrology, pulmonology, narcotic, acetaminophen, stearate, phosphate, peptide, medical imaging, imaging, contrast agent, delivery system, radiopharmaceutical, questcor pharmaceuticals inc., questcor pharmaceuticals, questcor | is related to: Kidney Health Initiative | Acute pain, Chronic pain, Brain disease, Autoimmune diease, Inflammatory disease | Wikidata: Q30273990, grid.482334.a, nlx_158397, ISNI: 0000 0004 4652 5312 | https://ror.org/00467td76 | SCR_003986 | Mallinckrodt plc | 2026-08-15 11:22:46 | 2 | ||||||
|
Public Health England; London; United Kingdom Resource Report Resource Website 10+ mentions |
Public Health England; London; United Kingdom (RRID:SCR_003905) | PHE | institution | An executive agency of the Department of Health in the United Kingdom to protect and improve the nation''s health and well-being, and reduce health inequalities. It employs 5,500 staff, who are mostly scientists, researchers and public health professionals. They have 15 local centers and 4 regions (north of England, south of England, Midlands and east of England, and London). They work closely with public health professionals in Wales, Scotland and Northern Ireland, and internationally. Its formation came as a result of reorganization of the National Health Service (NHS) in England. It took on the role of the Health Protection Agency, the National Treatment Agency for Substance Misuse and a number of other health bodies. They are responsible for: * making the public healthier by encouraging discussions, advising government and supporting action by local government, the NHS and other people and organisations * supporting the public so they can protect and improve their own health * protecting the nation''s health through the national health protection service, and preparing for public health emergencies * sharing information and expertise with local authorities, industry and the NHS, to help them make improvements in the public''s health * researching, collecting and analyzing data to improve our understanding of health and come up with answers to public health problems * reporting on improvements in the public''s health so everyone can understand the challenge and the next steps * helping local authorities and the NHS to develop the public health system and its specialist workforce | public health, health, well-being |
is related to: Predict-TB has parent organization: United Kingdom Department of Health |
Crossref funder ID: 501100002141, nlx_158245, ISNI: 0000 0004 5909 016X, Wikidata: Q7257402, grid.271308.f | https://ror.org/00vbvha87 | SCR_003905 | Health Protection Agency, Health Protection Agency; England; United Kingdom, HPA, Public Health England | 2026-08-15 11:22:41 | 17 | |||||||
|
DaVita Resource Report Resource Website 10+ mentions |
DaVita (RRID:SCR_003980) | DaVita | commercial organization | Healthcare company. Commercial dialysis provider with offerings that include in-center hemodialysis, in-center nocturnal dialysis, peritoneal dialysis, home hemodialysis, vascular access management, chronic kidney disease education, and renal diet assistance. Information on dialysis and chronic kidney disease, including informative articles and animated learning modules, and recipes for the dialysis diet are also available. Take advantage of their discussion forum, Find a Dialysis Center tool, DaVita GFR Calculator and more. | dialysis, health care, kidney, diet, clinical, administrative service | is related to: Kidney Health Initiative | Chronic kidney disease, End stage renal disease | nlx_158385 | SCR_003980 | DaVita Inc, DaVita.com, DaVita Healthcare Partners Inc., DaVita Kidney Care, DaVita Inc. | 2026-08-15 11:22:46 | 35 | |||||||
|
Shire Resource Report Resource Website 10+ mentions |
Shire (RRID:SCR_003984) | Shire | commercial organization | Global specialty biopharmaceutical company that focuses on developing treatments for conditions where the impact of their medicines can make an immediate and tangible difference for patients. They provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. This might be a therapy to treat an extremely rare and life-threatening disease like Hunter syndrome or Fabry disease; or a medicine for a specialist condition like ADHD or ulcerative colitis which if not treated effectively, can dramatically affect the lives of the patient and their whole family.Shire was acquired by Takeda Pharmaceutical company on January 8, 2019. | pharmaceutical, fibrotech therapeutics pty ltd., fibrotech therapeutics pty ltd, fibrotech therapeutics, fibrotech, medicine, drug |
is related to: Kidney Health Initiative is related to: Takeda Pharmaceutical Company Limited |
nlx_158391 | SCR_003984 | Takeda Pharmaceutical, Shire plc, Fibrotech Therapeutics | 2026-08-15 11:22:39 | 15 | ||||||||
|
FAST BioMedical Resource Report Resource Website 1+ mentions |
FAST BioMedical (RRID:SCR_003983) | commercial organization | A clinical stage company developing a timely, precise, and convenient method for measuring plasma volume and glomerular filtration rate (GFR). They focus on development and commercialization of a patented technology for quantifying clinically relevant parameters that have been challenging or impossible to measure in the past. The company is currently developing technology for quantifying volume status and kidney function in a clinically actionable timeframe. Their technology could have a significant impact on the treatment of patients with acute kidney injury (AKI) and chronic kidney disease (CKD). | clinical, kidney function, plasma volume, glomerular filtration rate, kidney | is related to: Kidney Health Initiative | Acute kidney injury, Chronic kidney disease | grid.505053.6, nlx_158390 | https://ror.org/04rmmkk14 | SCR_003983 | 2026-08-15 11:22:46 | 3 | ||||||||
|
ChemoCentryx Resource Report Resource Website 10+ mentions |
ChemoCentryx (RRID:SCR_003976) | commercial organization | A biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Each drug candidate is a small molecule designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biopharmaceutical, oral administration, medicine, small molecule, chemokine, chemo-attractant receptor, clinical, drug, oral drug | is related to: Kidney Health Initiative | Autoimmune disease, Inflammatory disorder, Cancer | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158383, grid.452218.8, ISNI: 0000 0004 0408 7502 | https://ror.org/04gp12571 | SCR_003976 | ChemoCentryx Inc, ChemoCentryx Inc. | 2026-08-15 11:22:46 | 43 | ||||||
|
C. R. Bard Resource Report Resource Website 1+ mentions |
C. R. Bard (RRID:SCR_003975) | BARD, BCR | commercial organization | A multinational developer, manufacturer, and marketer of medical technologies specializing in the manufacture of vascular, urology, oncology and surgical specialty products. BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs. Bard is perhaps best known for having introduced the Foley catheter. (Adapted from Wikipedia) | medical equipment, vascular, urology, oncology, surgical, medical technology, medical, clinical | is related to: Kidney Health Initiative | Cancer | nlx_158382 | SCR_003975 | C. R. Bard Inc., C.R. Bard Inc., C. R. Bard Inc, CR Bard, C.R. Bard Inc, C.R. Bard, CR Bard Inc. | 2026-08-15 11:22:42 | 2 | |||||||
|
ClinMet Resource Report Resource Website 1+ mentions |
ClinMet (RRID:SCR_003979) | ClinMet | commercial organization | THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021.Organization that uses metabolomics to provide pharmaceutical companies with clinically relevant and practical insight into drug response and safety for renal and cardiovascular diseases, obesity and diabetes. Their combination of skills to achieve exhaustive understanding of a disease along with detailed clinical insights, signature panel of urine-based metabolomic biomarkers, proprietary metabolomics and computational expertise will accelerate the speed and success rate of drug development. ClinMet helps drug developers to efficiently transform promising compounds into safe and effective medicines. Their efficacy and toxicity indices enable pharmaceutical companies to make better clinical trial-related decisions and provide an increased understanding of a drug''s mechanism of action. | metabolomics, drug, mechanism of action, clinical, clinical trial, drug efficacy, toxicity, drug discovery, drug development, kidney, safety, efficacy, medicine | is related to: Kidney Health Initiative | nlx_158384 | SCR_003979 | Clinical Metabolomics Inc, Clinical Metabolomics Inc. | 2026-08-15 11:22:43 | 1 | ||||||||
|
Diamyd Medical Resource Report Resource Website 1+ mentions |
Diamyd Medical (RRID:SCR_003930) | DMYD B | commercial organization | A diabetes company active in the field of pharmaceutical development. The Company develops the diabetes vaccine Diamyd with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd to global Phase III trials, leading to one of Sweden''s largest biotech agreements ever. The company has secured an exclusive license for a patent application for the specific combination therapy GAD plus the endogenous substance GABA, which has demonstrated favorable results in preclinical trials. The license also encompasses rights for the therapeutic use of GABA to treat diabetes and other inflammation-related disorders. | pharmaceutical, drug development, drug | is related to: Pharma-Planta Consortium | Type 1 diabetes, Diabetes | nlx_158298 | SCR_003930 | Diamyd Medical AB | 2026-08-15 11:22:41 | 2 | |||||||
|
POLYMUN Scientific Resource Report Resource Website 1+ mentions |
POLYMUN Scientific (RRID:SCR_003926) | POLYMUN | commercial organization | A private commercial company generating revenues by contract development and manufacturing biopharmaceuticals as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (??63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. Its core competence is the development and manufacture of biopharmaceuticals, using both mammalian and microbial cell technology. A fine example are Polymun''s broadly neutralizing HIV-1 antibodies produced in CHO cells. Other examples are recombinant human and porcine trypsin produced in yeast. Cell culture was also the basis for the development of a live attenuated influenza vaccine produced in Vero cells which led to the further investigation in genetically modified influenza viruses used as carrier for foreign epitopes (HIV, TB). Also the innovative liposome technology was initiated in order to optimize the formulation of the pharmacologically potent enzyme SOD, produced by Polymun in E. coli. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies. | biopharmaceutical, liposomal formulation, drug manufacture, pharmaceutical, liposome, drug | is related to: Pharma-Planta Consortium | nlx_158293 | http://www.polymun.com/ | SCR_003926 | Polymun Scientific Immunbiologische Forschung GmbH | 2026-08-15 11:22:38 | 2 | |||||||
|
BC Childrens Hospital Foundation Resource Report Resource Website 1+ mentions |
BC Childrens Hospital Foundation (RRID:SCR_003925) | BCCHF | institution | Funding resource that raises funds to support BC Children's Hospital, Sunny Hill Health Centre for Children and the Child and Family Research Institute. The Foundation also works with Sunny Hill's Board of Directors to manage the Sunny Hill Foundation for Children. In 2013, BC Children's Hospital Foundation received donations from more than 150,000 people and had revenues of over $83 million. | child, pediatric, clinical | grid.498685.e, Wikidata: Q4835281, nlx_158291, ISNI: 0000 0001 1432 0695 | https://ror.org/01xesb955 | SCR_003925 | BC Children's Hospital Foundation | 2026-08-15 11:22:44 | 2 | ||||||||
|
Institute of Cancer Research Resource Report Resource Website 10+ mentions |
Institute of Cancer Research (RRID:SCR_003912) | ICR | institution | Academic cancer research center, a postgrad college, and a charity in the United Kingdom that is making discoveries that defeat cancer. With their partners The Royal Marsden NHS Foundation Trust they form the largest comprehensive cancer center in Europe and perform high quality and original basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide. The ICR offers comprehensive, modern facilities for research and studentships supported by the Wellcome Trust, MRC, CRUK and EPSRC and the ICR''s own resources which are awarded on a competitive basis. The ICR offers postgraduate research degrees (MPhil, PhD and MD (Res)) and a modular postgraduate taught degree in oncology aimed at clinicians undertaking specialist training in the field of Clinical or Medical Oncology leading to a Postgraduate Certificate, Postgraduate Diploma or MSc in Oncology. | clinical, medical, oncology |
is related to: PREDECT has parent organization: University of London; London; United Kingdom is parent organization of: FLIGHT is parent organization of: MoKCa- Mutations of Kinases in Cancer |
Cancer | nlx_158259, grid.18886.3f, Wikidata: Q6039999, ISNI: 0000 0001 1271 4623 | https://ror.org/043jzw605 | SCR_003912 | The Institute of Cancer Research | 2026-08-15 11:22:38 | 12 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
